Semaglutide for MASH: RCT Shows FAST Score & MRI-PDFF Improvements (2026)

For patients and clinicians exploring semaglutide peptide therapy beyond weight management, a compelling new randomized controlled trial (RCT) published in *Alimentary Pharmacology & Therapeutics* adds important evidence to the conversation. The SAMARA trial demonstrates that semaglutide 2.4 mg weekly — the same subcutaneous dose used in obesity management — produces measurable, statistically significant improvements in liver health markers in patients with metabolic dysfunction-associated steatohepatitis (MASH). What makes this study particularly relevant to clinical peptide therapy practice is its use of non-invasive testing (NIT) to both identify eligible patients and track treatment response, opening a more practical pathway for real-world monitoring without the burden of liver biopsy.

The SAMARA trial was a multicentre, randomised, double-blind, placebo-controlled study conducted across several academic medical centers in the United States, including UC San Diego, UC San Francisco, Indiana University, and Washington University. Fifty-five participants were enrolled and randomised to either semaglutide 2.4 mg subcutaneously once weekly or matching placebo over 52 weeks.

Eligible participants met AASLD criteria for MASLD with a BMI of 27 kg/m² or higher (or ≥ 25 kg/m² with prediabetes or type 2 diabetes), liver stiffness by vibration-controlled transient elastography (VCTE) of at least 8 kPa, and a FAST score of 0.5 or above — indicating at-risk MASH. The primary outcome was change in FAST score from baseline to end of treatment. Secondary endpoints included body weight, MRI-measured proton density fat fraction (MRI-PDFF), ALT, and HbA1c.

The study population was 55% women, 20% had type 2 diabetes, and the mean baseline BMI was 40.2 kg/m² — a cohort representative of patients commonly evaluated in metabolic and longevity medicine practices.

The SAMARA trial is noteworthy for several reasons. First, it is among the first RCTs to validate a fully non-invasive testing strategy — using FAST score and MRI-PDFF — to both select patients with suspected at-risk MASH and objectively quantify their response to semaglutide therapy. This is a meaningful advancement because liver biopsy, while historically the gold standard for MASH diagnosis and staging, carries procedural risk and is impractical for routine monitoring.

Second, the breadth of metabolic benefit observed — spanning liver fat, liver enzymes, glycemic control, and lipids — reinforces semaglutide's systemic mechanism of action as a GLP-1 receptor agonist. These findings suggest that in appropriately selected patients, semaglutide may simultaneously address multiple components of cardiometabolic risk, not liver pathology alone.

Third, the 52-week duration and rigorous double-blind design lend credibility to these findings in a way that observational studies and case series cannot.

If you are considering semaglutide peptide therapy and carry a diagnosis — or suspicion — of fatty liver disease or MASH, this study provides direct, high-quality evidence that semaglutide may offer benefit well beyond the scale. Patients with elevated liver enzymes, high BMI, prediabetes, or known hepatic steatosis on imaging are precisely the population studied in SAMARA.

In clinical practice, this means a physician can use accessible non-invasive tools — including FibroScan-based VCTE and FAST scoring, along with standard blood panels measuring ALT, AST, and HbA1c — to assess whether you are a candidate for semaglutide and to monitor your progress meaningfully over time. You do not necessarily need a liver biopsy to get started or to confirm that therapy is working.

For patients pursuing peptide therapy as part of a broader longevity and metabolic optimization program, the SAMARA findings reinforce that semaglutide's benefits operate at a systemic level — metabolic, hepatic, and cardiovascular simultaneously.

As with all research, context matters. The SAMARA trial enrolled only 55 participants, limiting statistical power and generalizability. The study population had a high mean BMI (40.2 kg/m²), so findings may not translate directly to leaner individuals with MASH. The trial did not include liver biopsy endpoints, meaning histological resolution of fibrosis or steatohepatitis cannot be confirmed from this data alone. Additionally, the 52-week follow-up period does not address long-term outcomes such as fibrosis regression or cardiovascular events. Larger, longer trials will be necessary to fully characterize semaglutide's disease-modifying potential in MASH.